Formulation Design of an HPMC-Based Sustained Release Tablet for Pyridostigmine Bromide as a Highly Hygroscopic Model Drug and its In Vivo/In Vitro Dissolution Properties

REFERENCES

• Alderman D. A. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Tech. Prod. Mfr. 1984; 5: 1–9
   Web of Science ®Google Scholar
• Bodmeier R. Tableting of coated pellets. Eur. J. Pharm. Biopharm. 1997; 43(1)1–8
   Web of Science ®Google Scholar
• Chopra R., Alderborn G., Podczeck F., Newton J. M. The influence of pellet shape and surface properties on the drug release from uncoated and coated pellets. Int. J. Pharm. 2002; 239(1–2)171–178
   PubMedGoogle Scholar
• Chuo W. H., Tsai T. R., Cham T. M. The investigation of the internal structure and release behavior of tablets compressed by nifedipine-loaded albumin microspheres. Pharmazie. 1998; 53(2)104–110
   Web of Science ®Google Scholar
• Engineer S., Shao Z. J., Khagani N. A. Temperature/humidity sensitivity of sustained-release formulations containing Kollidon®SR. Drug Dev. Ind. Pharm. 2004; 30(10)1089–1094
   PubMed Web of Science ®Google Scholar
• Ford J. L., Rubinstein M. H., Hogan J. E. Formulation of sustained-release promethazine hydrochloride tablets using hydroxypropyl-methylcellulose matrices. Int. J. Pharm. 1985; 24(2–3)327–338
   Google Scholar
• Gandhi R., Kaul C. L., Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm. Sci. Technol. Today 1999; 2(1)160–170
   Google Scholar
• Hegazy N., Demirel M., Yazan Y. Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int. J. Pharm. 2002; 242(1–2)171–174
   PubMed Web of Science ®Google Scholar
• Hogan J. E. Hydroxypropyl-methylcellulose sustained-release technology. Drug Dev. Ind. Pharm. 1989; 15(6)975–999
   Web of Science ®Google Scholar
• Huang Y. B., Tsai Y. H., Yang W. C., Chang J. S., Wu P. C., Takayama K. Once-daily propranolol extended-release tablet dosage form: Formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm. 2004; 58(3)607–614
   PubMed Web of Science ®Google Scholar
• Huang Y. T., Lai T. F., Tsai T. R., Cheng C. J., Chuo W. H., Cham T. M. Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigate of in vitro/in vivo dissolution properties. Drug Dev. Ind. Pharm. 2007; 33(4)1–14
   Google Scholar
• Kim H., Fassihi R. A new ternary polymeric matrix system for controlled drug delivery of highly soluble drugs: I. Diltiazem hydrochloride. Pharm. Res. 1997; 14(10)1415–1421
   PubMed Web of Science ®Google Scholar
• Lee P. I. Kinetics of drug release from hydrogel matrices. J. Control. Release. 1985; 2(2)277–288
   Google Scholar
• Lee B. J., Ryu S. G., Cui J. H. Formulation and release characteristics of hydroxypropyl-methylcellulose matrix tablet containing melatonin. Drug Dev. Ind. Pharm. 1999; 25(4)493–501
   PubMed Web of Science ®Google Scholar
• Li S., Lin S., Daggy B. P., Mirchandani H. L., Chien Y. W. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery systems using factorial design. Int. J. Pharm. 2003; 253(1–2)13–22
   PubMedGoogle Scholar
• Lin A. Y., Muhammad N. A., Pope D., Augsburger L. L. A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit® NE30D. Pharm. Dev. Tech. 2003; 8(3)277–287
   PubMed Web of Science ®Google Scholar
• Lundqvist Å. E. K., Podczeck F., Newton J. M. Influence of disintegrant type and proportion on the properties of tablets produced from mixtures of pellets. Int. J. Pharm. 1997; 147(1)95–107
   Google Scholar
• Maejima T., McGinity J. W. Influences of film additives on stabilizing drug release rates from pellets coated with acrylic polymers. Pharm. Dev. Technol. 2001; 6(2)211–221
   PubMed Web of Science ®Google Scholar
• McEvoy G. Pyridostigmine Bromide. AHFS Drug Information, G. K. McEvoy. American Society of Hospital Pharmacists, Inc, Bethesda, MD 1992; 630–632
   Google Scholar
• Michaelis H. C. Determination of pyridostigmine plasma concentrations by high-performance liquid chromatography. J. Chromatogr. 1990; 534(1)291–294
   PubMed Web of Science ®Google Scholar
• Montgomery D. C. The 2^k factorial design: Design and analysis of experiments. John Wiley & Sons, New York 1996; 290–294
   Google Scholar
• Peppas N. A., Sahlin J. J. A simple equation for the description of solute release, III. Coupling of diffusion and relaxation. Int. J. Pharm. 1989; 57(2)169–172
   Web of Science ®Google Scholar
• Qiu Y., Cheskin H. S., Engh K. R., Poska R. P. Once-a-day controlled release dosage form of divalproex sodium I: Formulation design and in vitro/in vivo investigations. J. Pharm. Sci. 2003; 92(6)1166–1173
   PubMed Web of Science ®Google Scholar
• Rao Y. M., Veni J. K., Jayasagar G. Formulation and Evaluation of Diclofenac Sodium Using Hydrophilic Matrices. Drug Dev. Ind. Pharm. 2001; 27(8)759–766
   PubMed Web of Science ®Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinder or discs. J. Control. Release. 1987a; 5(1)23–36
   Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release. 1987b; 5(1)37–42
   Google Scholar
• Sánchez-Lafuente C., Furlanetto S., Fernández-Arévalo M., Alvarez-Fuentes J., Rabasco A. M., Faucci M. T., Pinzauti S., Mura P. Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. Int. J. Pharm. 2002; 237(1–2)107–118
   PubMed Web of Science ®Google Scholar
• Sung K. C., Nixon P. R., Skoug J. W., Ju T. R., Gao P. E., Topp M., Patel M. V. Effect of formulation variables on drug and polymer release from HPMC-based matrix tablets. Int. J. Pharm. 1996; 142(1)53–60
   Web of Science ®Google Scholar
• Takka S., Sakr A., Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release 2003; 88(1)147–157
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (FDA). Guidance for industry, dissolution testing of IR solid oral dosage forms, 1997.
   Google Scholar
• United States Food and Drug Administration (FDA). Pyridostigmine Bromide Package Insert, 2002.
   Google Scholar
• United States Food and Drug Administration (FDA). FDA approves PB as pretreatment against nerve gas, 2003.
   Google Scholar
• Vazquez M. J., Perez-Marcos B., Gomez-Amoza J. L., Martinez-Pacheco R., Souto C., Concheiro A. Influence of technological variables on release drugs from hydrophilic matrices. Drug Dev. Ind. Pharm. 1992; 18(11–12)1355–1375
   Web of Science ®Google Scholar
• Vervaet C., Baert L., Remon J. P. Extrusion-spheronisation a literature review. Int. J. Pharm. 1995; 116(2)131–146
   Web of Science ®Google Scholar
• Wanger J., Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 1964; 53(11)1392–1404
   PubMed Web of Science ®Google Scholar